

Monthly Healthcare Megatrend Market Report

January 2022

HANetf & GInsGlobal

HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF

WELL

59bps

IE00BJQTJ848

Product Inception Date: 04/04/2019

For Professional Clients Only. Capital at risk.

All data as of 31.12.21

This report was written by, and is the opinion of, the WELL Fund Partner, GinsGlobal

Key Takeaways

- Wide dispersion of subtheme performance in 2021 – Medical Devices (14.3%), Neuroscience (28.7%) versus Telemedicine (down 39.7%) and Gene Sequencing down 20%¹
- Top monthly contributors across multiple themes - iRhythm up 5.7% (Trackers), Intuitive Surgical up 5.4% (Robotic)¹
- Ten subthemes, Equal Weight across all 104 current holdings.¹
- WELL's returns driven by Medical Device holdings (26.5% weight), Biotech (26.4%), Genome Sequencing (18.6%), Neuroscience (9.8%) & Telemedicine (5.4%).¹
- Holdings increasingly global – with the US at 70.6%, Japan 8.3%, China 3.1% and Europe 14.1%. (Source; HANetf December Fact Sheet - WELL)
- Digital Healthcare expecting more Big Tech deals – latest Oracle \$30bn Cerner electronic data deal.²
- US Healthcare digitizing as spending hugely inefficient ~ 20% of GDP. (Source <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-andReports/NationalHealthExpendData/NationalHealthAccountsHistorical>)

Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Please note that all performance figures are showing net data.

Macro Outlook

- Increasing prevalence of chronic diseases and the growing awareness re fitness and wellness - driving adoption of innovative wearable medical devices globally.³
- Telemedicine fast growth expected to reate beaten down stocks like Teledoc.⁴
- North America dominates Telemedicine - double the size of Europe and 6 times larger than Asia-Pacific.⁵
- Digital Health estimated at \$152.5bn in 2020, projected to reach a revised size of US\$456.9bn by 2026 - CAGR of 18.8% annually¹
- Global DNA sequencing market size to hit ~\$40bn by 2030, just \$8.4bn currently.⁶

Sub-Themes	YTD	December
Telemedicine	-39.7%	-1.7%
Genome Sequencing	-20.0%	-1.2%
Medical Devices	14.3%	4.0%

¹ Source: INDXX. Data as of 31.12.2021

² <https://www.ft.com/content/9bf80646-fdfb-44ff-ab51-7a4236091afa>

³ <https://www.globenewswire.com/news-release/2021/12/15/2352334/0/en/With-Astonishing-26-4-CAGR-Wearable-Medical-Devices-Market-Size-2021-2028-Worth-USD-195-57-Billion.html>

⁴ <https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality>

⁵ Telemedicine Market Size & Share, Growth Outlook 2021-2027 (gm insights.com)

⁶ <https://www.globenewswire.com/en/news-release/2021/02/24/2181661/0/en/DNA-Sequencing-Market-Size-to-Hit-Around-US-40-64-Bn-by-2030.html>

Neuroscience	28.7%	3.4%
Bioinformatics	-35.6%	-9.4%
Biological Engineering	-5.8%	1.4%
Healthcare Analytics	-25.4%	-0.9%
Robotics	-56.2%	2.9%
Healthcare Trackers	-53.9%	-7.1%

Past performance is no guarantee of future performance. Please note that all performance figures are showing net data. Source: INDXX. Data as of 31.12.2021

Company Name	Sub-Themes	December(Contribution to Return)
IRHYTHM TECHNOLOGIES INC	Healthcare Trackers	5.72%
INTUITIVE SURGICAL INC	Robotics	5.39%
TABULA RASA HEALTHCARE INC	Healthcare Analytics	5.32%
ACADIA PHARMACEUTICALS INC	Neuroscience	2.16%
NEXTGEN HEALTHCARE INC	Telemedicine	1.85%
XENON PHARMACEUTICALS INC	Neuroscience	1.70%
MEIRAGTX HOLDINGS PLC	Genome Sequencing	1.56%
1 LIFE HEALTHCARE INC	Telemedicine	1.29%
INTRA-CELLULAR THERAPIES INC	Biological Engineering	1.17%
SAGE THERAPEUTICS INC	Neuroscience	0.93%

HAN-GINS Indxx Healthcare Innovation UCITS ETF – Performance

As of 31.12.21

	1M	3M	6M	YTD	12M	2y	3Y	SI
HAN-GINS Indxx Healthcare Megatrend	1.22%	-7.68%	-13.17%	-6.77%	-6.77%	19.19%	NA	32.43%
<i>Indxx Global NextGen Healthcare Index (NTR)</i>	1.26%	-7.71%	-13.27%	-6.71%	-6.71%	20.15%	51.55%	34.27%

Past performance for the index is in USD. Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Investors should read the prospectus of the Issuer (“Prospectus”) before investing and should refer to the section of the Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in this product. Source: Bloomberg / HANetf. Data as of 31/12/2021. **Please note that all performance figures are showing net data.**

Product Details

HAN-GINS Indxx Healthcare Megatrend UCITS ETF (WELL) is a UCITS compliant Exchange Traded Fund domiciled in Ireland.

WELL tracks the Indxx Global NextGen Healthcare Index (Net Total Return), an index designed to measure the performance of large, mid and small-capitalisation companies primarily listed on an exchange in Developed and Emerging Markets that are involved in the Advanced Life Sciences & Smart Healthcare sector.

Please remember that the value of your investment may go down as well as up and past performance is no indication of future performance.

Visit the WELL Fund Page for more information.

Exchange	BBG Code	RIC	ISIN	Valoren	SEDOL	Currency	TER
London Stock Exchange	WELL LN	HAWELL.L	IE00BJQTJ848	-	BJVBGL7	USD	0.59%
London Stock Exchange	WELP LN	WELP.L	IE00BJQTJ848	-	BJVBGM8	GBP	0.59%
Borsa Italiana	WELL IM	WELL.MI	IE00BJQTJ848	-	BHRWXD1	EUR	0.59%
Deutsche Boerse Xetra	W311 GY	W311.DE	IE00BJQTJ848	-	BJ02354	EUR	0.59%
SIX Swiss Exchange	WELL SW	WELL.S	IE00BJQTJ848	47284465	BMYC3R3	CHF	0.59%



Anthony Ginsberg, GinsGlobal Index Funds

Anthony Ginsberg is the co-creator of the HAN-GINS Healthcare Megatrend UCITS ETF (WELL), enabling investors to gain exposure to over 100 leading healthcare companies across eight subthemes at the forefront of medical innovation. WELL tracks a rules-based index to identify and select companies involved in the field of innovative healthcare.

Anthony Ginsberg is the Managing Director of GinsGlobal Investment Management, a global asset management company offering a broad range of innovative index-linked products, for both retail and institutional investors. GinsGlobal designs index products for a number of leading financial institutions, including global insurers, banks and asset managers. GinsGlobal was founded in 2000 and has operations in North America, Africa, Middle East and Asia-Pacific.

Important Information

Communications issued in the UK (ETFs and ETCs)

The content in this document is issued by HANetf Limited (“HANetf”) and approved by Privium Fund Management (UK) Limited (“Privium”). HANetf are an appointed representative of Privium, which is authorised and regulated by the Financial Conduct Authority.). HANetf is registered in England and Wales with registration number 10697042.

Communications issued in the European Economic Area (“EEA”) relating to ETFs

The content in this document is issued by HANetf Management Limited (“HML”) acting in its capacity as management company of HANetf ICAV. HML is authorised and regulated by the Central Bank of Ireland. HML is registered in Ireland with registration number 621172.

Communications issued in the EEA relating to ETCs

The content in this document is issued by Walnut Financial Services B.V. and OAKK Capital Partners B.V. (“OAKK”), an investment firm authorized and regulated by the Authority for the Financial Markets in The Netherlands. OAKK is registered in the Netherlands with registration number 24425154.

The Issuers

1. HANetf ICAV, an open-ended Irish collective asset management vehicle issuing under the terms in the Prospectus and relevant Supplement for the ETF approved by the Central Bank of Ireland (“CBI”) (“ETF Prospectus”) is the issuer of the ETFs. Investors should read the current version of the ETF Prospectus before investing and should refer to the section of the ETF Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETFs. Any decision to invest should be based on the information contained in the ETF Prospectus.

2. HANetf ETC Securities plc, a public limited company incorporated in Ireland, issuing:

- i. the precious metals ETCs under the terms in the Base Prospectus approved by both the Central Bank of Ireland (“CBI”), the UK Financial Conduct Authority (“FCA”) (“ETC Prospectus”) and the final terms of the relevant precious metals series (together, “ETC Securities Documentation”); and
- ii. the carbon securities ETCs under the terms in the Base Prospectus approved by the FCA (“FCA ETC Prospectus”) and the final terms of the relevant carbon allowance (together, “FCA ETC Securities Documentation”).

Investors should read the latest versions of the ETC Securities Documentation and the FCA ETC Securities Documentation before investing and should refer to the section of the Base Prospectuses entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETCs. Any decision to invest should be based on the information contained in the ETC Securities Documentation and the FCA ETC Securities Documentation.

3. ETC Issuance GmbH, a limited liability company incorporated under the laws of the Federal Republic of Germany, issuing under the terms in the Prospectus approved by the Bundesanstalt für Finanzdienstleistungsaufsicht (“BaFin”) and the final terms (“Cryptocurrency Prospectus”) is the issuer of the ETCM ETCs. Investors should read the latest version of the Cryptocurrency Prospectus before investing and should refer to the section of the Cryptocurrency Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the ETCs contained in the Cryptocurrency Prospectus. Any decision to invest should be based on the information contained in the Cryptocurrency Prospectus.

The ETF Prospectus, ETC Securities Documentation, FCA ETC Securities Documentation and Cryptocurrency Prospectus can all be downloaded from www.hanetf.com.

This communication has been prepared for professional investors, but the ETCs and ETFs set out in this communication (“Products”) may be available in some jurisdictions to any investors. Please check with your broker or intermediary that the relevant Product is available in your jurisdiction and suitable for your investment profile.

Past performance is not a reliable indicator of future performance. The price of the Products may vary and they do not offer a fixed income.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements.

The content of this document is for information purposes and for your internal use only, and does not constitute an investment advice, recommendation, investment research or an offer for sale nor a solicitation of an offer to buy any Product or make any investment.

An investment in an exchange traded product is dependent on the performance of the underlying asset class, less costs, but it is not expected to track that performance exactly. The Products involve numerous risks including among others, general market risks relating to underlying adverse price movements in an Index (for ETFs) or underlying asset class and currency, liquidity, operational, legal and regulatory risks. In addition, in relation to Cryptocurrency ETCs, these are highly volatile digital assets and performance is unpredictable.

The information contained on this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of securities in the United States or any province or territory thereof, where none of the Issuers (as defined below) or their Products are authorised or registered for distribution and where no prospectus of any of the Issuers has been filed with any securities commission or regulatory authority. No document or information on this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the Issuers, nor any securities issued by it, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

Information for Investors of the EEA with regards to unregistered ETC Products:

In relation to each Member State of the EEA (each a “Relevant State”), the relevant Issuer has represented and agreed that it has not made and will not make an offer of the unregistered Products which are the subject of the offering contemplated by the relevant prospectus to the public in that Relevant State other than at any time:

- to any legal entity which is a qualified investor as defined in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”);

- to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by the relevant Issuer for any such offer; or
- in any other circumstances falling within Articles 1(3), 1(4) and/or 3(2)(b) of the Prospectus Regulation (as may be locally implemented),

provided that no such offer of the unregistered Products shall require the relevant Issuer to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

For the purposes of the provision above, the expression an “offer of Products to the public” in relation to any unregistered Products in any Relevant State means the communication in any form and by means of sufficient information on the terms of the offer and the unregistered Products to be offered so as to enable an investor to decide to purchase or subscribe for the unregistered Products, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129, and includes any relevant implementing measure in the Relevant State.

SPECIFIC DISCLAIMERS FOR INVESTORS IN CERTAIN EU COUNTRIES:

AUSTRIA

The relevant prospectus is not an approved securities prospectus pursuant to the Prospectus Regulation and the information contained herein does not constitute an offer to grant or a solicitation of an offer to subscribe to the unregistered Products. No prospectus pursuant to the Prospectus Regulation has been or will be drawn up and approved in the Republic of Austria and no prospectus pursuant to the Prospectus Regulation has been or will be passported into the Republic of Austria as the unregistered Products will be offered in the Republic of Austria in reliance on an exemption from the prospectus publication requirement under the Prospectus Regulation. Subject to and in accordance with the provisions of the Prospectus Regulation, the unregistered Products may therefore not be publicly offered or (re)sold in the Republic of Austria without a prospectus being published, or an applicable exemption from such requirement being relied upon. Each subscriber to the unregistered Products represents to the relevant Issuer that such subscriber will only (re)sell, offer or transfer the unregistered Products in accordance with applicable Austrian securities and capital markets law legislation governing the issue, (re)sale and offering of securities. Because of the foregoing limitations, each subscriber to unregistered Products undertakes to inform himself/herself about and to observe, any such restrictions. The information contained herein is not binding, solely for the information of the recipients of this document and must not be reproduced, distributed to any other person (including the press and any other media) or published, in whole or in part, for any purpose. This document is a marketing communication and has not been prepared in accordance with legal requirements designed to promote the independence of investment research. This document is not intended to provide a basis of any credit or other evaluation of the relevant Issuer and its business and should not be considered as a personal recommendation for any recipient of this document to purchase the unregistered Products as it does not take into account the particular investment objectives, financial situation or needs of any specific recipient. Each investor contemplating purchasing any unregistered Products therefore represents to make its own independent investigation of relevant Issuer / unregistered Products and of the suitability of an investment in the unregistered Product in light of their particular circumstances and represents to seek independent professional advice, including tax advice. This document is distributed under the condition that the above obligations are accepted by the recipient and complied with.

BELGIUM

The offering of the unregistered Products has not been and will not be notified to the Belgian Financial Services and Markets Authority (Autoriteit voor Financiële Diensten en Markten/Autorité des Services et Marchés Financiers) nor has the relevant prospectus been, nor will it be, approved by the Belgian Financial Services and Markets Authority. The unregistered Products may not be distributed in Belgium by way of an offer of the unregistered Products to the public, as defined in Article 4, §2 of the Act of 11 July 2018 relating to Public Offers of Investment Instruments, as amended or replaced from time to time, save in those circumstances (commonly called "private placement") set out in Article 1 §(4) of the Prospectus Regulation. This document may be distributed in Belgium only to such investors for their personal use and exclusively for the purposes of this offering of the unregistered Products. Accordingly, this document may not be used for any other purpose nor passed on to any other investor in Belgium. The relevant Issuer represents and agrees that it will not offer for sale, sell or market the unregistered Products in Belgium otherwise than in conformity with the Act of 11 July 2018 and Prospectus Regulation.

FRANCE

Neither this document nor any other offering material relating to the unregistered Products has been submitted to the clearance procedures of the Autorité des Marchés Financiers ("AMF") or to the competent authority of another member state of the European Economic Area and subsequently notified to the AMF. The unregistered Products have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France unless in compliance with article 1(4) of the Prospectus Regulation on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, as implemented into French law. Neither this document nor any other offering material relating to the unregistered Products has been or will be:

- released, issued, distributed or caused to be released, issued or distributed to the public in France; or
- used in connection with any offer for subscription or sale of the unregistered Products to the public in France.

Such offers, sales and distributions will be made in France only:

- to qualified investors (investisseurs qualifiés) and/or to a restricted circle of investors (cercle restreint d'investisseurs), in each case investing for their own account, all as defined in, and in accordance with, articles L.411-2, 1°, L.411-2-1, D.411-2-1, II and III, D.411-4, D.744-1, D.754-1 and D.764-1 of the French Code monétaire et financier ("CMF"); or
- to investment services providers authorised to engage in portfolio management on behalf of third parties; or
- in a transaction that, in accordance with article L.411-2 of the CMF and article 211-2 of the Règlement Général of the AMF, does not constitute a public offer.

The unregistered Products may be resold directly or indirectly to the public in France, only in compliance with the aforementioned articles of the CMF. This document and any other offering materials are strictly confidential and may not be distributed to any person or entity other than the recipients hereof.

ITALY

The offering of the unregistered Products has not been registered pursuant to Italian securities legislation. Any offer, sale or delivery of the unregistered Products in the Republic of Italy or distribution of copies of this the relevant prospectus or any other document relating to the unregistered Products in the Republic of Italy must be: (i) made by an investment firm, bank or financial intermediary permitted to conduct such activities in the Republic of Italy in accordance with the Financial Services Act, CONSOB Regulation No. 20307 of 15 February 2018 and Legislative Decree No. 385 of 1 September 1993, as amended; and (ii) in compliance with any other applicable laws and regulations. Please note that, in accordance with Article 100-bis of the Financial Services Act, the subsequent distribution of the unregistered Products on the secondary market in Italy must be made in compliance with the rules on offers of securities to be made to the public provided under the Financial Services Act and the Regulation 11971/1999. Failure to comply with such rules may result, inter alia, in the sale of such unregistered Products being declared null and void and in the liability of the intermediary transferring the unregistered Products for any damages suffered by the investors.

POLAND

Recipients of the relevant prospectus or any related documents, including but not limited to other offering materials, should be aware that neither the relevant prospectus nor any related documents have been approved by the Financial Supervision Commission in the Republic of Poland (the "FSC") and the FSC has not received notification from any other competent authority in the European Union concerning the approval of the relevant prospectus together with a copy of the approved relevant prospectus and translation of its summary section. This document and any related documents, including offers or sales of the unregistered Products, may not be distributed in the Republic of Poland, unless the unregistered Products are publicly offered within the meaning of the Prospectus Regulation on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, only to (i) qualified investors, (ii) investors who acquire securities for a total consideration of at least EUR 100,000 per investor, for each separate offer, or (iii) if the denomination of offered securities per unit amounts to at least EUR 100,000.

SPAIN

Neither the securities nor the relevant prospectus have been approved or registered with the Spanish Securities Markets Commission (Comision Nacional del Mercado de Valores). Accordingly, the securities may not be offered or sold in Spain

except in circumstances which do not constitute a public offering of securities within the meaning of article 35 of the restated text of the Securities Market Act, approved by means of the Spanish Royal Decree 4/2015, of 23 October, and supplemental rules enacted thereunder.

Information for Investors outside of the EEA with regards to unregistered ETC Products:

SWITZERLAND

The unregistered Products are not intended to be offered, sold, marketed or otherwise made available to and shall not be offered, sold, marketed or otherwise made available to any private client in Switzerland other than in the context of a discretionary investment management agreement within the meaning of article 58(2) of FinSA and article 83 of the Swiss Financial Services Ordinance. No key information document within the meaning of article 58 FinSA has been prepared with respect to the unregistered Products.

The decision and amount to invest in any Product should take into consideration your specific circumstances after seeking independent investment, tax and legal advice. We do not control and are not responsible for the content of third-party websites.

We believe the information in this document is based on reliable sources, but its accuracy cannot be guaranteed. The views expressed are the views of Hanetf at time of publication and may change. Neither Privium nor HANetf is liable for any losses relating to the accuracy, completeness or use of information in this communication, including any consequential loss.